Medicine Overview of Triovix 150mg+200mg+300mg Tablet
Triovix is a combination of antiretrovirals medicines. It is prescribed to treat HIV (human immunodeficiency virus) infection. It boosts up the immunity to fight against HIV to manage or treat AIDS (acquired immunodeficiency syndrome).
Triovix restricts the growth of HIV in the body and reduces the risk of getting HIV-related complications to improve the lifespan of an individual. The medicine can be taken with or without food. Taking these medicines regularly at the same time increases their effectiveness. A dose of this medicine should not be missed as it can affect your recovery. It is important to complete the full course of the treatment until your doctor advises you to stop it. Sudden discontinuation of the treatment may affect the potency of the medicine.
The most common side effects of this medicine are headaches, nasal congestion, diarrhea, nausea, weakness and tiredness, cough, and rash. These side effects are generally temporary, but if they persist or become serious inform your doctor. This medicine can also make you feel lazy or weak, so it is advised to avoid driving. Drinking plenty of fluid can help you to cope up with the side effects, so stay hydrated.
Before starting with the treatment, you should consult your doctor if you are pregnant or breastfeeding, or have any health condition. Your doctor may suggest regular blood tests to check your blood counts, kidney and liver functions, and other health conditions. If you are HIV positive, you should not breastfeed or share personal belongings like razors or toothbrushes. Consult your doctor to know about safe sex methods in order to prevent transmission of HIV during intercourse.
- HIV infection
- Nausea
- Vomiting
- Diarrhea
- Headache
- Tiredness
- Insomnia (difficulty in sleeping)
- Rash
- Muscle damage
- Anemia (low number of red blood cells)
- Decreased white blood cell count (neutrophils)
-
Triovix is a combination of three medicines which slows down or stops the progression of HIV infections.
-
Take it on an empty stomach, preferably at bedtime, to reduce side effects.
-
Skipping doses increases the risk of treatment failure. Make sure that you take all your doses at the correct time.
-
Triovix may cause dizziness or sleepiness. Don’t drive or do anything requiring concentration until you know how it affects you.
-
Triovix can cause birth defects. Use effective contraception while taking Triovix and 12 weeks after stopping it.
-
It may cause weakening of your bones. Exercise regularly and take calcium and vitamin D supplements as suggested by your doctor.
-
Your doctor may monitor your kidney and liver functions regularly. Inform your doctor if you develop symptoms such as abdominal pain, loss of appetite, darkened urine or yellowing of the eyes or skin.
-
Do not stop taking Triovix without your doctor’s advice.
Adult: PO: One tablet twice daily.
Renal impairment:
CrCl (ml/min)
<50 Avoid
Neutrophil count <0.75 x 109/l; haemoglobin levels <7.5 g/dl or 4.65 mmol/l. Lactation.
Synergistically reduce viral resistance and inhibit reverse transcriptase via DNA chain termination.
Lamivudine: NRTI; following phosphorylation, inhibits HIV reverse transcriptase by viral DNA chain termination; cytosine analog.
Zidovudine: NRTI; interferes with HIV viral RNA-dependent DNA polymerase (inhibits viral replication); thymidine analog.
Nevirapine: Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI); activity against HIV-1 by binding to reverse transcriptase, and thereby blocking RNA- and DNA-dependent DNA polymerase actions including HIV-1 replication.
Does not require intracellular phosphorylation for activity.
Renal and hepatic impairment; poor bone marrow reserve prior to treatment; risk of opportunistic infection; patients (especially obese women) with risk factors for or active liver disease. Patients with low body wt should avoid the combined formulation. Separate formulations of lamivudine or zidovudine should not be given at the same time as the combined formulation. If dose adjustment is necessary for either component, separate formulations should be used. Monitor haematological parameters (advanced disease: 2 wkly for 1st 3 mth of treatment, then monthly; early disease: 1-3 mthly), LFTs, mean cell volume, serum creatinine kinase, viral load, CD4 counts and blood lactate levels.
Patient to report any sore throat, nausea, vomiting, unexplained bruising or bleeding. Maintain adequate hydration (2-3 L/day) unless fluid restricted. Withdraw treatment if symptomatic hyperlactaemia, metabolic/lactic acidosis, progressive heptomegaly or rapidly elevating aminotransferase levels occur. Cases of lactic acidosis and hepatic steatosis syndrome have been reported in pregnancy. Monitor hepatic enzymes and electrolytes regularly during 3rd trimester.
Headache, malaise and fatigue, fever or chills, nausea, diarrhoea, anorexia, abdominal pain, neuropathy, insomnia and other sleep disorders, dizziness, depressive disorders, nasal signs and symptoms, skin rashes, musculoskeletal pain, myalgia, arthralgia; anaemia, neutropenia and leucopenia (particularly at high doses of zidovudine; 1200-1500 mg/day), usually seen 4-5 wk after therapy commencing; respiratory symptoms eg rapid and/or deep breathing; if symptomatic hyperlactatemia, metabolic/lactic acidosis, progressive hepatomegaly, or rapidly elevating aminotransferase levels occur, withdraw treatment; mitochondrial damage leading to hyperlactatemia and hyperlipasemia; lipodystrophy; immune reactivation syndrome, osteonecrosis.
Potentially Fatal: Lactic acidosis associated with liver failure and pancreatitis (normally after several mth of treatment); haematological toxicity (eg neutropenia and severe anaemia).
Zidovudine: acyclovir and valacyclovir may increase CNS depression. Increased risk of haematologic toxicity with ganciclovir, valganciclovir, dapsone, doxorubicin, vincristine and vinblastine. Doxorubicin may reduce phophorylation; fluconazole may increase levels/effects; increased risk of hepatic decompensation or haematologic toxicities with interferon-? and ribavirin (also increases risk of pancreatitis and lactic acidosis). Methadone may increase effects/levels. Increased risk of myalgia, malaise and/or fever, maculopapular rash and effects/levels with probenecid. Stavudine may decrease antiviral activity; valproic acid may increase plasma levels (AUC increased by 80%).
Lamivudine: Increased risk of hepatic decompensation or haematologic toxicities with interferon-? and ribavirin (also increases risk of mitochondrial toxicity, pancreatitis and lactic acidosis). Ganciclovir and valganciclovir may increase effects and toxicity; sulfamethoxazole/trimethoprim may increase AUC and decrease clearance (increasing levels and effects).
Reviews
Clear filtersThere are no reviews yet.